tiprankstipranks
Trending News
More News >
Climb Bio (CLYM)
NASDAQ:CLYM
US Market

Climb Bio (CLYM) Technical Analysis

Compare
62 Followers

Technical Sentiment

Overall Consensus
Buy
12Bullish
4Neutral
6Bearish
Technical Analysis Consensus
Buy
4Bullish
4Neutral
2Bearish
Moving Average Consensus
Buy
8Bullish
0Neutral
4Bearish
Climb Bio’s (CLYM) Moving Averages Convergence Divergence (MACD) indicator is 0.02, suggesting Climb Bio is a Sell.
Climb Bio’s (CLYM) 20-Day exponential moving average is 1.26, while Climb Bio’s (CLYM) share price is $1.34, making it a Buy.
Climb Bio’s (CLYM) 50-Day exponential moving average is 1.30, while Climb Bio’s (CLYM) share price is $1.34, making it a Buy.

Climb Bio (CLYM) Pivot Points

Jun 11, 2025, 07:30 AM
Name
S3
S2
S1
Pivot Points
R1
R2
R3
Classic
1.08
1.18
1.28
1.38
1.48
1.58
1.68
Fibonacci
1.18
1.25
1.30
1.38
1.45
1.50
1.58
Pivot points are a technical analysis tool used by traders to identify potential support and resistance levels in financial markets. Pivot points are calculated based on the previous day's high, low, and close prices, and are used to help traders identify levels at which the price may reverse or continue to trend.

Climb Bio (CLYM) Moving Averages

Jun 11, 2025, 07:30 AM
Period
Simple
Exponential
MA5
1.31Buy
1.31Buy
MA10
1.25Buy
1.28Buy
MA20
1.24Buy
1.26Buy
MA50
1.24Buy
1.30Buy
MA100
1.41Sell
1.70Sell
MA200
2.92Sell
3.18Sell
Climb Bio’s (CLYM) 10-Day exponential moving average is 1.28, while Climb Bio’s (CLYM) share price is $1.34, making it a Buy.
Climb Bio’s (CLYM) 100-Day exponential moving average is 1.70, while Climb Bio’s (CLYM) share price is $1.34, making it a Sell.
Climb Bio’s (CLYM) stock price is $1.34 and Climb Bio’s (CLYM) 50-day simple moving average is 1.24, creating a Buy signal.
Climb Bio’s (CLYM) stock price is $1.34 and Climb Bio’s (CLYM) 100-day simple moving average is 1.41, creating a Sell signal.
Climb Bio’s (CLYM) stock price is $1.34 and Climb Bio’s (CLYM) 200-day simple moving average is 2.92, creating a Sell signal.

Climb Bio (CLYM) Technical Indicators

Jun 11, 2025, 07:30 AM
Name
Value
Implied Action
RSI (14)
56.90
Neutral
STOCH (9,6)
57.42
Neutral
STOCHRSI (14)
57.42
Neutral
MACD (12,26)
0.02
Sell
ADX (14)
14.45
Buy
Williams %R
-41.94
Buy
CCI (14)
184.78
Sell
ATR (14)
0.10
-
Ultimate Oscillator
42.99
Neutral
ROC
5.51
Buy
Climb Bio’s (CLYM) Relative Strength Index (RSI) is 56.90, creating a Neutral signal.
Climb Bio’s (CLYM) Trend Strength Indicator (ADX) is 14.45, creating a Buy signal.
Climb Bio’s (CLYM) Commodity Channel Index (CCI) is 184.78, creating a Sell signal.
Climb Bio’s (CLYM) Price Rate of Change (ROC) is 5.51, creating a Buy signal.

FAQ

Is CLYM a Buy, Hold, or Sell?
Based on CLYM’s technical indicators, CLYM is a Buy.
    What is CLYM’s RSI (14)?
    CLYM’s RSI (14) is 56.90, which suggests CLYM is a Neutral.
      What is CLYM’s MACD?
      CLYM’s MACD is 0.02, which suggests CLYM is a Sell.
        What is CLYM’s 5-day moving average?
        CLYM’s 5-day moving average is 1.31, which suggests CLYM is a Buy.
          What is CLYM’s 20-day moving average?
          CLYM 20-day moving average is 1.24, which suggests CLYM is a Buy.
            What is CLYM’s 50-day moving average?
            CLYM’s 50-day moving average is 1.24, which suggests CLYM is a Buy.
              What is CLYM’s 200-day moving average?
              CLYM’s 200-day moving average is 2.92, which suggests CLYM is a Sell.
                What is CLYM’s Williams % R (14)?
                CLYM’s Williams % R (14) is -41.94, which suggests CLYM is a Buy.
                  What is CLYM’s CCI (14)?
                  CLYM’s CCI (14) is 184.78, which suggests CLYM is a Sell.
                    What am I Missing?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis